Literature DB >> 27491589

Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats.

Steven J Simmons1, Taylor A Gentile2, Lili Mo2, Fionya H Tran2, Sisi Ma3, John W Muschamp4.   

Abstract

Tobacco smoking is the leading cause of preventable death in the United States. Nicotine is the principal psychoactive ingredient in tobacco that causes addiction. The structures governing nicotine addiction, including those underlying withdrawal, are still being explored. Nicotine withdrawal is characterized by negative affective and cognitive symptoms that enhance relapse susceptibility, and suppressed dopaminergic transmission from ventral tegmental area (VTA) to target structures underlies behavioral symptoms of nicotine withdrawal. Agonist and partial agonist therapies help 1 in 4 treatment-seeking smokers at one-year post-cessation, and new targets are needed to more effectively aid smokers attempting to quit. Hypothalamic orexin/hypocretin neurons send excitatory projections to dopamine (DA)-producing neurons of VTA and modulate mesoaccumbal DA release. The effects of nicotinic receptor blockade, which is commonly used to precipitate withdrawal, on orexin neurons remain poorly investigated and present an attractive target for intervention. The present study sought to investigate the effects of nicotinic receptor blockade on hypothalamic orexin neurons using mecamylamine to precipitate withdrawal in rats. Separate groups of rats were treated with either chronic nicotine or saline for 7-days at which point effects of mecamylamine or saline on somatic signs and anxiety-like behavior were assessed. Finally, tissue from rats was harvested for immunofluorescent analysis of Fos within orexin neurons. Results demonstrate that nicotinic receptor blockade leads to reduced orexin cell activity, as indicated by lowered Fos-immunoreactivity, and suggest that this underlying cellular activity may be associated with symptoms of nicotine withdrawal as effects were most prominently observed in rats given chronic nicotine. We conclude from this study that orexin transmission becomes suppressed in rats upon nicotinic receptor blockade, and that behavioral symptoms associated with nicotine withdrawal may be aided by intervention upon orexinergic transmission.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addiction; Fos; Hypocretin; Hypothalamus; Mecamylamine; Nicotine withdrawal; Orexin

Mesh:

Substances:

Year:  2016        PMID: 27491589      PMCID: PMC5817994          DOI: 10.1016/j.bbr.2016.07.053

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  80 in total

1.  Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal.

Authors:  Ainhoa Plaza-Zabala; África Flores; Rafael Maldonado; Fernando Berrendero
Journal:  Biol Psychiatry       Date:  2011-08-10       Impact factor: 13.382

Review 2.  Drug addiction: the yin and yang of hedonic homeostasis.

Authors:  G F Koob
Journal:  Neuron       Date:  1996-05       Impact factor: 17.173

Review 3.  Molecular and cellular aspects of nicotine abuse.

Authors:  J A Dani; S Heinemann
Journal:  Neuron       Date:  1996-05       Impact factor: 17.173

4.  Dramatic decreases in brain reward function during nicotine withdrawal.

Authors:  M P Epping-Jordan; S S Watkins; G F Koob; A Markou
Journal:  Nature       Date:  1998-05-07       Impact factor: 49.962

5.  Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine.

Authors:  Gemma Navarro; César Quiroz; David Moreno-Delgado; Adam Sierakowiak; Kimberly McDowell; Estefanía Moreno; William Rea; Ning-Sheng Cai; David Aguinaga; Lesley A Howell; Felix Hausch; Antonio Cortés; Josefa Mallol; Vicent Casadó; Carme Lluís; Enric I Canela; Sergi Ferré; Peter J McCormick
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

6.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

7.  Adolescent rats are resistant to adaptations in excitatory and inhibitory mechanisms that modulate mesolimbic dopamine during nicotine withdrawal.

Authors:  Luis A Natividad; Matthew W Buczynski; Loren H Parsons; Oscar V Torres; Laura E O'Dell
Journal:  J Neurochem       Date:  2012-10-01       Impact factor: 5.372

8.  Rodent model of nicotine abstinence syndrome.

Authors:  D H Malin; J R Lake; P Newlin-Maultsby; L K Roberts; J G Lanier; V A Carter; J S Cunningham; O B Wilson
Journal:  Pharmacol Biochem Behav       Date:  1992-11       Impact factor: 3.533

9.  Time course study of the effects of chronic nicotine infusion on drug response and brain receptors.

Authors:  M J Marks; J A Stitzel; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1985-12       Impact factor: 4.030

10.  Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study.

Authors:  Riccardo Polosa; Pasquale Caponnetto; Jaymin B Morjaria; Gabriella Papale; Davide Campagna; Cristina Russo
Journal:  BMC Public Health       Date:  2011-10-11       Impact factor: 3.295

View more
  2 in total

Review 1.  Neuropeptide systems and new treatments for nicotine addiction.

Authors:  Adriaan W Bruijnzeel
Journal:  Psychopharmacology (Berl)       Date:  2016-12-28       Impact factor: 4.530

Review 2.  Nicotinic Cholinergic System in the Hypothalamus Modulates the Activity of the Hypothalamic Neuropeptides During the Stress Response.

Authors:  Burcu Balkan; Sakire Pogun
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.